Skip to main content
. 2016 Jul 9;6(11):1753–1767. doi: 10.7150/thno.15616

Figure 6.

Figure 6

Immunofluorescent labeling of GFAP (white), CD11b (red) and TSPO (green) in the ischemic area, shown as three channels. The data show temporal evolution of TSPO in microglial and astrocytic cells at day 7 after MCAO in vehicle (left column, n=5), SAS (middle column, n=7) and S-4-CPG-treated rats (right column, n=8). GFAP-positive astrocytes do not change after treatments (A). CD11b-reactive microglia/macrophages (B) and TSPO receptor (C) decrease after MCAO in SAS and S-4-CPG-treated rats. (D) Merged images of three immunofluorescent antibodies. The number of CD11b-reactive microglia/macrophages expressing TSPO decrease at day 7 after daily treatment with SAS and S-4-CPG (E). The number of GFAP-reactive astrocytes expressing TSPO shows similar values following treatment (F). *p<0.05 and **p<0.01 compared with vehicle. Scale bars, 5 μm.